Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
Warner-admin (talk | contribs) |
||
Line 50: | Line 50: | ||
|- | |- | ||
|} | |} | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[ | + | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506467/ Drilon et al. 2020 (LIBRETTO-001)] |
+ | |2017-2018 | ||
| style="background-color:#91cf61" |Phase 1/2 (RT) | | style="background-color:#91cf61" |Phase 1/2 (RT) | ||
|- | |- | ||
Line 71: | Line 73: | ||
<!-- #'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract] --> | <!-- #'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract] --> | ||
− | # '''LIBRETTO-001:''' Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. [https://doi.org/10.1056/nejmoa2005653 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32846060 PubMed] NCT03157128 | + | # '''LIBRETTO-001:''' Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. [https://doi.org/10.1056/nejmoa2005653 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506467/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32846060 PubMed] NCT03157128 |
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Non-small cell lung cancers]] | [[Category:Non-small cell lung cancers]] |
Revision as of 00:07, 21 July 2022
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
7 regimens on this page
7 variants on this page
|
Advanced or metastatic disease
Pralsetinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Gainor et al. 2021 (ARROWRET) | 2017-2020 | Phase 1/2 (RT) |
Note: this trial is denoted as ARROWRET to distinguish from other trials of the same name. This is the phase II dosing.
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
- Pralsetinib (Gavreto) 400 mg PO once per day
Continued indefinitely
References
- ARROWRET: Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-969. Epub 2021 Jun 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. link to original article PubMed NCT03037385
Selpercatinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Drilon et al. 2020 (LIBRETTO-001) | 2017-2018 | Phase 1/2 (RT) |
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
- Selpercatinib (Retevmo) by the following weight-based criteria:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article link to PMC article PubMed NCT03157128